

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/39 // 39/29, 39/12, 31/715	A1	(11) International Publication Number: WO 96/26741 (43) International Publication Date: 6 September 1996 (06.09.96)
(21) International Application Number: PCT/EP96/00681 (22) International Filing Date: 15 February 1996 (15.02.96) (30) Priority Data: 9503863.4 25 February 1995 (25.02.95) GB (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM BIOLOGICALS S.A. [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): HAUSER, Pierre [BE/BE]; (BE). GARCON, Nathalie, Marie-Joséphé, Claude [FR/BE]; (BE). DESMONS, Pierre [BE/BE]; SmithKline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). (74) Agent: DALTON, Marcus, Jonathan, William; SmithKline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: HEPATITIS B VACCINE (57) Abstract A novel vaccine formulation is provided, comprising a hepatitis B component, particularly hepatitis B surface antigen, in combination with aluminum phosphate and 3 de-O-acylated monophosphoryl lipid A.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic			SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

HEPATITIS B VACCINE

The present invention relates to novel vaccine formulations, methods for preparing them and to their use in therapy. In particular the present invention relates to novel
5 formulations for treating Hepatitis infections and to combination vaccine formulations including a Hepatitis B vaccine component.

Viral hepatitis, caused by the A, B, C, D, and E hepatitis viruses, is a very common viral illness. Via the B and C viruses, in particular, it is also responsible
10 for many cases of liver cancer. Thus the development of effective vaccines is critical and, despite notable successes, is still an on-going task. A review on modern hepatitis vaccines, including a number of key references, may be found in the Lancet, May 12th 1990 at page 1142 ff (Prof A.L.W.F. Eddleston). See also 'Viral Hepatitis and Liver Disease' (Vyas, B.N., Dienstag, J.L., and Hoofnagle, J.H., eds, Grune and Stratton, Inc. (1984) and 'Viral Hepatitis and Liver Disease'
15 (Proceedings of the 1990 International Symposium, eds F.B. Hollinger, S.M. Lemon and H. Margolis, published by Williams and Wilkins).

As used herein the expression 'hepatitis B antigen' is used to refer to any antigenic
20 material derived from a hepatitis B virus which may be used to induce immunity to the virus in humans.

Infection with hepatitis B virus (HBV) is a widespread problem but vaccines which can be used for mass immunisation are now available, for example the product
25 'Engerix-B' (SmithKline Beecham plc) which is obtained by genetic engineering techniques.

The preparation of Hepatitis B surface antigen (HBsAg) is well documented. See for example, Harford et al in Develop. Biol. Standard 54, page 125 (1983), Gregg et al in Biotechnology, 5, page 479 (1987), EP-A- 0 226 846, EP-A-0 299 108 and
30 references therein.

As used herein the expression 'Hepatitis B surface antigen' or 'HBsAg' includes any HBsAg antigen or fragment thereof displaying the antigenicity of HBV surface
35 antigen. It will be understood that in addition to the 226 amino acid sequence of the HBsAg S antigen (see Tiollais et al, Nature, 317, 489 (1985) and references therein) HBsAg as herein described may, if desired, contain all or part of a pre-S sequence as described in the above references and in EP-A- 0 278 940. In particular the

HBsAg may comprise a polypeptide comprising an amino acid sequence comprising residues 12-52 followed by residues 133-145 followed by residues 175-400 of the L-protein of HBsAg relative to the open reading frame on a Hepatitis B virus of ad serotype (this polypeptide is referred to as L*; see EP 0 414 374). HBsAg within
5 the scope of the invention may also include the preS1-preS2 -S polypeptide described in EP 0 198 474 (Endotronics) or analogues thereof such as those described in EP 0 304 578 (Mc Cormick and Jones). HBsAg as herein described can also refer to mutants, for example the 'escape mutant' described in WO 91/14703 or European Patent Application Publication Number 0 511 855 A1,
10 especially HBsAg wherein the amino acid substitution at position 145 is to arginine from glycine.

Normally the HBsAg will be in particle form. The particles may comprise for example S protein alone or may be composite particles, for example (L*,S) where
15 L* is as defined above and S denotes the S-protein of HBsAg. The said particle is advantageously in the form in which it is expressed in yeast.

Whilst experimental and commercially available Hepatitis vaccines, for example Engerix-B, afford excellent results it is an accepted fact that an optimal vaccine
20 needs to stimulate not only neutralising antibody but also needs to stimulate as effectively as possible cellular immunity mediated through T-cells. International Patent Application No. WO 93/19780, discloses combination vaccines with a hepatitis B component based on a hepatitis B surface antigen, aluminium hydroxide and 3-de-O-acylated monophosphoryl Lipid A. A formulation comprising
25 aluminium phosphate was not suggested.

Surprisingly, the present invention provides a formulation up to four times more potent than those described in WO 93/19780.

30 Accordingly the present invention provides a vaccine comprising a hepatitis B antigen in conjunction with 3-O-deacylated monophosphoryl lipid A (abbreviated herein to MPL) and aluminum phosphate.

35 3-O-deacylated monophosphoryl lipid A (or 3 De-O-acylated monophosphoryl lipid A) has formerly been termed 3D-MPL or d3-MPL to indicate that position 3 of the reducing end glucosamine is de-O-acylated. For preparation, see GB 2 220 211 A. Chemically it is a mixture of 3-deacylated monophosphoryl lipid A with 4, 5 or 6 acylated chains. Herein the term 3D-MPL (or d3-MPL) is abbreviated to MPL.

since 'MPL' is a Registered Trademark of Ribi Immunochem., Montana which is used by Ribi to denote unambiguously their 3-O-deacylated monophosphoryl lipid A product.

- 5 Preferably in the compositions of the present invention small particle MPL is used. Small particle MPL has a particle size generally less than 120 nm. Such preparations are described in International Patent Application No. WO 94/21292.

- 10 GB 2 220 211A mentions that the endotoxicity of the previously used enterobacterial lipopolysaccharides (LPS) is reduced while the immunogenic properties are conserved. However GB 2 220 211 cited these findings merely in connection with bacterial (Gram negative) systems.

- 15 Surprisingly, however, it has been found that vaccine compositions according to the invention comprising hepatitis B viral antigens have particularly advantageous properties as described herein.

- 20 A particular advantage is that the vaccine formulations of the invention are very effective in inducing protective immunity, even with very low doses of antigen.

- The new vaccine formulations allow immunogenicity enhancements equivalent to currently available hepatitis B formulations after two doses. In particular equivalent levels of antibodies were obtained in a human clinical trial after two doses of vaccine compared with three doses of Engerix-B.

- 25 They provide excellent protection against primary infection and stimulate advantageously both specific humoral (neutralising antibodies) and also effector cell mediated (DTH) immune responses.

- 30 A further important advantage is that vaccine compositions according to the invention may also be used as therapeutic vaccines.

- 35 The MPL as defined above will normally be present in the range of 10-100ug, preferably 25-50ug per dose wherein the Hepatitis B antigen will be typically present in a range 2-50ug per dose and the aluminum phosphate will be in the range 500ug (Al 3+) per dose.

An embodiment of the invention is HBsAg S antigen (for example as in Engerix-B) in admixture with MPL and aluminum phosphate as described herein below.

5 A further specific embodiment of the invention is HBsAg antigen as (L*,S) particles, defined herein above, in admixture with MPL and aluminum phosphate.

The invention in a further aspect provides a vaccine formulation as described herein for use in medical therapy, particularly for use in the treatment or prophylaxis of hepatitis viral infections. In a preferred aspect the vaccine according to the
10 invention is a therapeutic vaccine useful for the treatment of ongoing hepatitis B infections.

In another aspect, the hepatitis vaccine composition of the invention contains other antigens so that it is effective in the treatment or prophylaxis of one or more other
15 bacterial, viral or fungal infections.

Accordingly the hepatitis vaccine formulation according to an embodiment of the invention contains at least one other component selected from other hepatitis antigens, in particular hepatitis A antigen, or non-hepatitis antigens which are
20 known in the art to afford protection against one or more of the following: diphtheria, tetanus, pertussis, Haemophilus influenzae b (Hib), and polio. Antigens against meningitidis A, B, or C may also be included.

Preferably the vaccine according to the invention includes HBsAg as herein above
25 defined.

Particular combination vaccines within the scope of the invention include a DTP (diphtheria-tetanus-pertussis) -hepatitis B combination vaccine formulation, an Hib-Hepatitis B vaccine formulation, a DTP-Hib-Hepatitis B vaccine formulation and an
30 IPV (inactivated polio vaccine) -DTP-Hib-Hepatitis B vaccine formulation.

The hepatitis vaccine or the above combinations may advantageously include a component which is protective against Hepatitis A, especially the killed attenuated strain derived from the HM-175 strain as is present in Havrix.

35

Suitable components for use in such vaccines are already commercially available and details may be obtained from the World Health Organisation. For example the IPV component may be the Salk inactivated polio vaccine. The pertussis vaccine

may comprise whole cell or acellular product, formulated with Diphtheria and Tetanus antigen such as Infanrix DTPa, which comprises three B. pertussis antigens: 69KDa, pertussis Toxin (inactivated), and FHA.

- 5 In one aspect the hepatitis or combination vaccine according to the invention may be a paediatric vaccine.

Vaccine preparation is generally described in New Trends and Developments in Vaccines, edited by Voller et al., University Park Press, Baltimore, Maryland
10 U.S.A. 1978. Encapsulation within liposomes is described, for example, by Fullerton, US Patent 4,235,877. Conjugation of proteins to macromolecules is disclosed, for example, by Likhite, US Patent 4,372,945 and by Armor et al., US Patent 4,474,757.

- 15 The amount of antigen in each vaccine dose is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccinees. Such amount will vary depending on which specific antigens are employed. Generally it is expected that each dose will comprise 1-1000ug of total antigen, preferably 2-200ug. An optimal amount for a particular vaccine can be
20 ascertained by standard studies involving observation of antibody titres and other responses in subjects. Following an initial vaccination, subjects may receive one or more booster doses, for example after 2 and 6 months.

- In a further aspect of the present invention there is provided a method of
25 manufacture of a vaccine effective in preventing or treating hepatitis infection, wherein the method comprises mixing the hepatitis antigen as defined herein with aluminum phosphate and MPL.

- Using this method one or more additional components are preferably admixed with
30 HBsAg to provide a combination vaccine. Several methods of mixing the components may be used. In one method each antigen may be separately absorbed on aluminum phosphate and after a period of time MPL may be added to each before adding the blending solution.

- 35 It will be appreciated that the invention also provides a method of inducing neutralising antibody titres in the range of 10mU for hepatitis B in a human susceptible to or suffering from hepatitis B infection by administering a composition as herein defined in no more than two doses.

In another aspect, the invention provides the use of a composition as herein defined for the manufacture of a vaccine for the induction of neutralising antibodies in the range of 10mU for hepatitis B in humans preferably after no more than two doses.

5

The following examples illustrate the invention and its advantages.

Example 1: Hepatitis B vaccine formulation

MPL (3 de-O-acylated monophosphoryl lipid A) was obtained from Ribi
Immunochem Research Inc. Aluminum phosphate was obtained from Superphos
5 (Denmark).

MPL was resuspended in water for injection at a concentration varying from 0.2 to
3 mg/ml by sonication until the particles reach a size of between 80 and 200 nm as
measured by photo correlation light scattering.

10

1 to 20ug of HBsAg (S- antigen as in Engerix B) in phosphate buffer solution at 0.5
to 3mg/ml) is adsorbed on 5 to 1000ug of aluminum phosphate (solution at 3-6
 Al^{3+} mg/ml) for one hour at room temperature under agitation. The mixture was
stored at room temperature for 15 days and then maintained at 4°C before further
15 processing. Then 5 to 200ug of MPL (solution 0.2 to 10mg/ml) were added to the
solution. Volume and osmolarity were adjusted to 500 to 1000ul with water for
injection and saline. Thiomersal (1% w/v) is added up to a final concentration of
0.005% to give the final product.

20 A similar formulation was prepared by using as the HBsAg component the
composite (L*,S) antigen as defined herein above. In this formulation the
bacteriostatic agent was 2-phenoxyethanol.

Example 2: Clinical studies of Hepatitis B surface antigen formulated with 3 deacylated monophosphoryl lipid A and Aluminium phosphate

5 In clinical testing, various hepatitis B surface antigen containing vaccines were compared. The following groups are considered:

Group 1 HBsAg (20 µg)/MPL (50µg)/AlPO₄ (Al:500 µg)/Thiomersal (50µg)/150 mM NaCl/pH 6.1 in 1ml, formulated as in example 1.

Group 2 HBsAg (20 µg)/MPL (50µg)/Al(OH)₃ (Al:100 µg)/Thiomersal (50µg)/10 mM phosphate buffer + 150 mM NaCl/pH 6.8 in 1ml.

Group 3 HBsAg (20 µg)/MPL (50µg)/Al(OH)₃ (Al:500 µg)/Thiomersal (50µg)/10 mM phosphate buffer + 150 mM NaCl/pH 6.8 in 1 ml.

Group 4 Engerix like
HBsAg (20 µg)/MPL (0µg)/Al(OH)₃ (Al:500 µg)/Thiomersal (50µg)/10 mM phosphate buffer + 150 mM NaCl/pH 6.8 in 1 ml.

10

Group 5 HBsAg (20 µg)/MPL (0µg)/AlPO₄ (Al:500 µg)/Thiomersal (50µg)/150 mM NaCl/pH 6.1 in 1ml.

The Volunteers aged 18 to 40 years old were recruited for participation in the trial. Each group (about 60 adults per group at day 0) was vaccinated intramuscularly in the deltoid region at day 0 and 2 months later. A sample of blood was collected
15 before the first injection, one and two months after the first injection and 1, 2 and 4 months after the second injection. The anti-HBs antibodies were measured using the AUSAB kit (Abbott) and a WHO reference calibrated in mIU/ml. Responders had a titre ≥ 1 mIU/ml. For each time point, the GMT (Geometric Mean Titre) was calculated for seroconverters.

20

Results

The GMT's are given in Table 1 for each vaccine and table 2 gives the ranking of the antibody titres in each group of vaccinees.

25

The GMT results (table 1) clearly show that after 2 doses of vaccine containing Al PO₄ + MPL (group 1), a more than 10 fold increase of the titers is observed after

the second dose compared with the titre reached using the commercial Engerix B (group 4). The anti-HBs response is also faster and 51 and 70% of vaccinees have a protective titre (10ml/U/ml) 1 and 2 months after the first dose (compared to 34 and 16% for Engerix B) (table 2). The addition of 3D-MPL to Engerix B (Group 3),
5 the use of AlPO₄ only (group 5) slightly improve the anti-HBS response (compared to Engerix B) but the titres are still 4 to 5 fold lower than with the Al PO₄ + MPL formulation. Adsorption of HBsAg on a reduced dose of Al (OH)₃ + MPL gives titres which are similar to those reached with Engerix B. Together, the results indicate that both Al PO₄ and MPL are necessary to have an optimal increase of the
10 anti-HBs response in vaccinees after only 2 doses.

TABLE 1

5 Seroconversion rates (%) and geometric mean anti-HBs antibody titre (GMT) of seroconverters: Preliminary analysis

Group	Timing	N	S+	%	GMT	CL 95% lower	CL 95% upper	Min titre	Max titre
1	Pre	59	0	0.0	0			0	0
	PI (m1)	53	46	86.8	12	9	8	1	410
	PI (m2)	53	50	94.3	18	13	26	1	140
	PII (m3)	53	53	100.0	2092	1356	3227	43	60000
	PII (m4)	39	39	100.0	1613	1074	2423	40	19620
	PII (m6)	25	25	100.0	890	582	1363	42	3900
2	Pre	59	0	0.0	0			0	0
	PI (m1)	53	31	58.5	17	10	32	1	1000
	PI (m2)	53	35	66.0	9	6	16	1	860
	PII (m3)	53	35	100.0	215	128	360	1	25000
	PII (m4)	40	40	100.0	122	74	201	2	2808
	PII (m6)	22	22	100.0	85	50	145	2	900
3	Pre	59	0	0.0	0			0	0
	PI (m1)	53	43	81.1	9	6	15	1	720
	PI (m2)	53	44	83.0	7	4	10	1	1040
	PII (m3)	53	53	100.0	527	332	838	3	10100
	PII (m4)	40	40	100.0	363	225	586	3	5638
	PII (m6)	24	24	100.0	177	99	316	9	2196
4	Pre	59	0	0.0	0			0	0
	PI (m1)	50	30	60.0	11	6	19	1	290
	PI (m2)	50	34	68.0	4	3	6	1	45
	PII (m3)	50	50	100.0	187	107	329	1	9500
	PII (m4)	42	42	100.0	211	127	350	5	10584
	PII (m6)	25	25	100.0	226	132	386	20	2595
5	Pre	59	0	0.0	0			0	0
	PI (m1)	52	30	57.7	12	6	25	1	1060
	PI (m2)	52	41	78.8	9	6	14	1	420
	PII (m3)	52	52	100.0	294	168	515	1	18000
	PII (m4)	41	41	100.0	287	158	521	2	15764
	PII (m6)	24	22	91.7	353	188	660	10	7701

TABLE 2

Distribution of individual anti-HBs antibody titres preliminary analysis

Group	Timing	N	> =10 n	%	> =100 n	%	> +1000 n	%
1	Pre	59	0	0.0	0	0.0	0	0.0
	PI (m1)	53	27	50.9	2	3.8	0	0.0
	PI (m2)	53	37	69.8	2	3.8	0	0.0
	PII (m3)	53	53	100.0	49	92.5	40	75.5
	PII (m4)	39	39	100.0	37	94.9	27	69.2
	PII (m6)	25	25	100.0	24	96.0	15	60.0
2	Pre	59	0	0.0	0	0.0	0	0.0
	PI (m1)	53	20	37.7	3	5.7	1	1.9
	PI (m2)	53	14	26.4	3	5.7	0	0.0
	PII (m3)	53	50	94.3	38	71.7	11	20.8
	PII (m4)	40	38	95.0	24	60.0	3	7.5
	PII (m6)	22	21	95.5	8	36.4	0	0.0
3	Pre	59	0	0.0	0	0.0	0	0.0
	PI (m1)	53	17	32.1	7	13.2	0	0.0
	PI (m2)	53	17	32.1	1	1.9	1	1.9
	PII (m3)	53	51	96.2	45	84.9	20	37.7
	PII (m4)	40	39	97.5	34	85.0	10	25.0
	PII (m6)	24	23	95.8	18	75.0	3	12.5
4	Pre	59	0	0.0	0	0.0	0	0.0
	PI (m1)	50	17	34.0	3	6.0	0	0.0
	PI (m2)	50	8	16.0	0	0.0	0	0.0
	PII (m3)	50	46	92.0	35	70.0	11	22.0
	PII (m4)	42	40	95.2	30	71.4	5	11.9
	PII (m6)	25	25	100.0	18	72.0	4	16.0
5	Pre	59	0	0.0	0	0.0	0	0.0
	PI (m1)	52	15	28.8	5	9.6	1	1.9
	PI (m2)	52	20	38.5	3	5.8	0	0.0
	PII (m3)	52	48	92.3	39	75.0	14	26.9
	PII (m4)	41	39	95.1	31	75.6	9	22.0
	PII (m6)	24	22	91.7	18	75.0	5	20.8

Claims

- 5 1. A vaccine composition comprising a hepatitis B antigen in conjunction with 3-O-deacylated monophosphoryl lipid A and aluminum phosphate.
2. A vaccine composition as claimed in Claim 1 wherein the antigen comprises Hepatitis B surface antigen (HBsAg) or a variant thereof.
- 10 3. A vaccine composition as claimed in Claim 2 wherein the HBsAg comprises the S antigen of HBsAg (226 amino acids).
4. A vaccine composition as claimed in Claim 3 wherein the HBsAg additionally
15 comprises a pre-S sequence.
5. A vaccine composition as claimed in Claim 3 or Claim 4 wherein the HBsAg is the composite particle of the formula (L*,S) wherein L* denotes a modified L protein of hepatitis B virus having an amino acid sequence comprising residues 12-
20 52 followed by residues 133-145 followed by residues 175-400 of the L protein and S denotes the S-protein of HBsAg.
6. A vaccine composition as claimed in any preceding claim comprising one or more hepatitis antigens and at least one other component selected from a hepatitis A
25 antigen or a non-hepatitis antigen which affords protection against one or more of the following: diphtheria, tetanus, pertussis, Haemophilus influenzae b (Hib), polio and meningitidis A, B, or C.
7. A vaccine composition according to Claim 6 selected from a DTP (diphtheria-tetanus-pertussis) HBsAg combination, an Hib-HBsAg combination, a DTP-Hib-HBsAg combination and an IPV (inactivated polio vaccine) -DTP-Hib-HBsAg
30 combination.
8. A vaccine composition according to claim 7 additionally comprising a hepatitis
35 A antigen.
9. A vaccine composition as claimed in any preceding claim wherein the 3-O-deacylated monophosphoryl lipid A is present in the range 10ug-100ug per dose.

10. A vaccine composition as claimed herein for use in medicine.
11. Use of a hepatitis B antigen in conjunction with 3-O-deacylated
5 monophosphoryl lipid A and aluminum phosphate in the manufacture of a
medicament for the prophylaxis or treatment of hepatitis infections.
12. A method of inducing neutralising antibody titres in the range of 10mU for
10 hepatitis B in a human susceptible to or suffering from hepatitis B infection by
administering a composition according to any one of claims 1 to 10.
13. The use of a composition according to any one of claims 1 to 10 for the
manufacture of a vaccine for the induction of neutralising antibodies in the range of
10mU for hepatitis B in humans.
15
14. A method of treating a human subject suffering from or susceptible to hepatitis
B infections comprising administering an effective amount of a vaccine according to
any of claims 1 to 10.
- 20 15. A method of treating a human subject suffering from ongoing hepatitis B
infection comprising administering an effective amount of a therapeutic vaccine
according to any of claims 1 to 10.
- 25 16. A process for the production of a vaccine as claimed in any one of claims 1 to
9 comprising absorbing Hepatitis B surface antigen on to aluminium phosphate and
then adding 3-O-de acylated monophosphoryl lipid A.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 96/00681

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K39/39 //A61K39/29,A61K39/12,A61K31/715

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,94 21292 (SMITHKLINE BEECHAM BIOLOGICALS (S.A.)) 29 September 1994 cited in the application see the whole document ---	1-16
Y	WO,A,93 19780 (SMITHKLINE BEECHAM BIOLOGICALS (S.A.)) 14 October 1993 see the whole document ---	1-16
Y	VACCINE, vol. 11, 1993, pages 383-387, XP002005418 PELLEGRINI, V. ET AL.: see page 385, right-hand column, line 22 - page 386, right-hand column, line 21 --- -/--	1-16

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search

12 June 1996

Date of mailing of the international search report

12.07.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Olsen, L

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 96/00681

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	VACCINE, vol. 10, 1992, pages 412-420, XP002005419 EWASYSKYN, M. ET AL.: see abstract see page 416, left-hand column, line 13 - page 417, right-hand column, line 10 see page 418, right-hand column, line 12 - line 31	1-16
A	--- GB,A,2 220 211 (RIBI IMMUNOCHEM RESEARCH INC.) 4 January 1990 cited in the application see the whole document -----	1-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/00681

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9421292	29-09-94	AU-B- 6426494	11-10-94
		BR-A- 9405957	12-12-95
		CA-A- 2157376	29-09-94
		CZ-A- 9502467	13-03-96
		EP-A- 0689454	03-01-96
		FI-A- 954514	22-09-95
		NO-A- 953759	22-09-95
		PL-A- 310598	27-12-95
		ZA-A- 9401957	31-01-95
WO-A-9319780	14-10-93	AU-B- 3751693	08-11-93
		CA-A- 2132833	14-10-93
		CN-A- 1085805	27-04-94
		CZ-A- 9402355	15-02-95
		EP-A- 0633784	18-01-95
		FI-A- 944442	26-09-94
		HU-A- 69931	28-09-95
		JP-T- 7505372	15-06-95
		NO-A- 943571	14-11-94
		SI-A- 9300149	31-12-93
		SK-A- 115294	07-06-95
GB-A-2220211	04-01-90	US-A- 4912094	27-03-90
		CA-A- 1317589	11-05-93
		DE-A- 3921416	04-01-90